首页> 美国卫生研究院文献>Protein Science : A Publication of the Protein Society >The effect of Arg306--Ala and Arg506--Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.
【2h】

The effect of Arg306--Ala and Arg506--Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.

机译:Arg306- Ala和Arg506- Gln替代在活化蛋白C和蛋白S灭活重组人因子Va中的作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Factor Va (fVa) is inactivated by activated protein C (APC) by cleavage of the heavy chain at Arg306, Arg506, and Arg679. Site-directed mutagenesis of human factor V cDNA was used to substitute Arg306-->Ala (rfVa306A) and Arg506-->Gln (rfVa506Q). Both the single and double mutants (rfVa306A/506Q) were constructed. The activation of these procofactors by alpha-thrombin and their inactivation by APC were assessed in coagulation assays using factor V-deficient plasma. All recombinant and wild-type proteins had similar initial cofactor activity and identical activation products (a factor Va molecule composed of light and heavy chains). Inactivation of factor Va purified from human plasma (fVaPLASMA) in HBS Ca2+ +0.5% BSA or in conditioned media by APC in the presence of phospholipid vesicles resulted in identical inactivation profiles and displayed identical cleavage patterns. Recombinant wild-type factor Va (rfVaWT) was inactivated by APC in the presence of phospholipid vesicles at an overall rate slower than fVaPLASMA. The rfVa306A and rfVa506Q mutants were each inactivated at rates slower than rfVaWT and fVaPLASMA. Following a 90-min incubation with APC, rfVa306A and rfVa506Q retain approximately 30-40% of the initial cofactor activity. The double mutant, rfVa306A/506Q, was completely resistant to cleavage and inactivation by APC retaining 100% of the initial cofactor activity following a 90-min incubation in the presence of APC. Recombinant fVaWT, rfVa306A, rfVa506Q, and rfVa306A/506Q were also used to evaluate the effect of protein S on the individual cleavage sites of the cofactor by APC. The initial rates of rfVaWT and rfVa306A inactivation in the presence of protein S were unchanged, indicating cleavage at Arg506 is not affected by protein S. The initial rate of rfVa506Q inactivation was increased, suggesting protein S slightly accelerates the cleavage at Arg306. Overall, the data demonstrate high specificity with respect to cleavage sites for APC on factor Va and demonstrate that cleavages of the cofactor at both Arg306 and Arg506 are required for efficient factor Va inactivation.
机译:通过切割Arg306,Arg506和Arg679的重链,激活蛋白C(APC)使因子Va(fVa)失活。人因子V cDNA的定点诱变用于取代Arg306-> Ala(rfVa306A)和Arg506-> Gln(rfVa506Q)。构建了单突变体和双突变体(rfVa306A / 506Q)。使用凝血因子V缺陷型血浆在凝血试验中评估了α-凝血酶对这些前因子的激活和APC对它们的灭活。所有重组蛋白和野生型蛋白均具有相似的初始辅因子活性和相同的激活产物(由轻链和重链组成的因子Va分子)。在磷脂囊泡存在下,通过APC对HBS Ca2 + + 0.5%BSA中或在条件培养基中从人血浆(fVaPLASMA)纯化的因子Va的灭活导致相同的灭活曲线并显示出相同的裂解模式。重组野生型因子Va(rfVaWT)在磷脂囊泡存在下被APC灭活,其总体速率低于fVaPLASMA。 rfVa306A和rfVa506Q突变体的失活速率均低于rfVaWT和fVaPLASMA。与APC孵育90分钟后,rfVa306A和rfVa506Q保留了约30-40%的初始辅助因子活性。在APC存在下孵育90分钟后,双突变体rfVa306A / 506Q对APC的切割和失活具有完全抗性,保留了100%的初始辅助因子活性。重组fVaWT,rfVa306A,rfVa506Q和rfVa306A / 506Q也用于评估蛋白S对APC辅助因子单个切割位点的影响。存在蛋白S时rfVaWT和rfVa306A失活的初始速率没有变化,这表明在Arg506处的切割不受蛋白S的影响。rfVa506Q失活的初始速率增加了,表明蛋白S稍微加速了Arg306的切割。总体而言,数据证明了在因子Va上针对APC的切割位点具有高度特异性,并证明在Arg306和Arg506上都需要辅因子的裂解才能有效地灭活因子Va。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号